MedGenesis Enters Into Agreement with Pfizer for Treatments for PD

(September 29, 2014) – MedGenesis Therapeutix Inc. announced that it has entered into an agreement with Pfizer Inc., granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson’s disease. MedGenesis’ unique therapeutic approach, delivers GDNF precisely to the regions of the brain where it is required via its CED technology. Read more…